There are currently 632 clinical trials in Louisville, Kentucky looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Louisville, Jewish Hospital, Norton Cancer Institute and Saints Mary and Elizabeth Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT04647916
Recruiting
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Jewish Hospital, Louisville, Kentucky +2 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04071457
Recruiting
Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Ste... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
08/11/2023
Locations: Jewish Hospital, Louisville, Kentucky +3 locations
Conditions: Multiple Myeloma
Register for Updates
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
NCT04205968
Recruiting
This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Jewish Hospital, Louisville, Kentucky +2 locations
Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8
Register for Updates
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: Jewish Hospital, Louisville, Kentucky +2 locations
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Register for Updates
VNS Prospective Neuromodulation of Autonomic, Immune and Gastrointestinal Systems
NCT03953768
Recruiting
Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for epilepsy in the 1990s and is commonly performed as an outpatient surgery. The mechanism of efficacy is not well understood; however it is increasingly recognized that electrical stimulation of the vagus nerve may impact other organ systems in the body including the immune, gastrointestinal and auton... Read More
Gender:
All
Ages:
Between 0 years and 60 years
Trial Updated:
08/04/2023
Locations: Norton Healthcare, Louisville, Kentucky +1 locations
Conditions: Autoimmune Diseases, Epilepsy, Autonomic Dysfunction, Inflammatory Bowel Diseases
Register for Updates
Effects of 5HTP on the Injured Human Spinal Cord
NCT04520178
Recruiting
This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability and motor function in individuals with spinal cord injuries of differing chronicity and severity. Participants will visit the lab on 4 separate occasions where they will be administered four different drugs in a randomized, double-blinded, placebo-controlled crossover design.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
08/03/2023
Locations: University of Louisville, Louisville, Kentucky
Conditions: Spinal Cord Injuries
Register for Updates
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
NCT05225584
Recruiting
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokineti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: Norton Cancer Institute, Louisville, Kentucky
Conditions: Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), Solid Tumors, T-cell Prolymphocytic Leukemia (T-PLL)
Register for Updates
Venetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Recruiting
The study is a multicenter, open label Phase I/II trial. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: University of Louisville, Louisville, Kentucky
Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: James Graham Brown Cancer Center- University of Louisville, Louisville, Kentucky
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
NCT03988439
Recruiting
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
07/25/2023
Locations: Bausch Site 3, Louisville, Kentucky
Conditions: Psoriasis
Register for Updates
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
NCT05219110
Recruiting
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E. coli (STEC) infection in children and adolescents when compared with traditional approaches (conservative fluid management).
Gender:
All
Ages:
Between 9 months and 21 years
Trial Updated:
07/21/2023
Locations: Norton Children's Hospital, Louisville, Kentucky
Conditions: Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Register for Updates